Hamilton Locke advised Tryptamine Therapeutics Limited (previously Exopharm Limited) (Company) on its acquisition and backdoor listing of Tryp Therapeutics Inc., a biotechnology entity previously listed on the Canadian Securities Exchange. The acquisition occurred by way of a Canadian plan of arrangement and included a A$6,500,000 public offer.
The Company is entering an exciting new field of research in difficult to treat disorders through the use of psychedelics. The Company aims to be at the forefront of research and development in the psychedelics field by pioneering an approach which aims to allow practitioners to control the precise quantity of the drug in patients’ blood levels.
Commenting on the acquisition, Hamilton Locke Partner Jeremy Newman said, “We’re excited to have assisted Tryptamine Therapeutics in their groundbreaking backdoor listing, being the first entity focussed on the development of psychedelics to successfully complete an initial offer on ASX. It’s rare to have the opportunity to be involved such a trailblazing listing and we look forward to assisting the Company in their ongoing work towards the treatment of fibromyalgia, irritable bowel syndrome and binge eating disorder.”
The team at Hamilton Locke was comprised of Jeremy O’Hara and Brendon Banks and led by Partner, Jeremy Newman
Read the full announcement here.
